RABBIT ANTI-P16INK4A ANTIBODY

Biochem/physiol Actions

Cyclin-dependent kinase inhibitor 2A (CDK4I) or p16INK4a is a negative regulator of cyclin dependant kinase 4 (CDK4) and CDK6 kinase activity and cell cycle progression. The ankyrin repeats (I–IV) are crucial for their interaction with CDK4 and CDK6. P16INK4a regulates the cell cycle by inhibiting cyclin/CDK complex formation and the phosphorylation of the retinoblastoma protein (pRb). P16INK4a is a tumor suppressor and its mutations are associated with malignancies such as melanoma and astrocytoma and are the cause of Li-Fraumeni syndrome.

Disclaimer

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.

General description

Cyclin-dependent kinase inhibitor 2A (CDK4I) or p16INK4a belongs to the Ink4 family of CDK inhibitors. The p16INK4agene is mapped to human chromosome 9p21. Structurally, p16INK4a comprises four ankyrin-type repeats (I–IV) .

Immunogen

The epitope recognized by PLA0178 maps to a region between residue 106 and 156 of human CDK4 inhibitor p16-INK4a using the numbering given in entry AAA92554.1 (GeneID 1029).

Other Notes

p16INK4a is a negative regulator of CDK4 and CDK6 kinase activity and cell cycle progression. P16INK4a regulates the cell cycle by inhibiting cyclin/CDK complex formation and the phosphorylation of the retinoblastoma protein (pRb). P16INK4a is a tumor suppressor associated with malignancies such as melanoma and astrocytoma and is the cause of Li-Fraumeni syndrome.

Physical form

Tris-buffered Saline containing 0.1% BSA containing 0.09% Sodium Azide